In the midst of a pandemic that has seen entire industries (airlines, rental cars, hotels) gutted, and others (restaurants, physical retail) on the brink of bankruptcy, investors are hungry for one kind of data above all others: Vaccine effectiveness and safety. So when Moderna (MRNA) released a bit of supplemental data on Phase 1 clinical trials of its mRNA-1273 vaccine against coronavirus Wednesday, the investment bankers from JPMorgan were right there, pens in hand, and ready to take notes.Moderna made its latest reveal at a public meeting of the Advisory Committee on Immunization Practices (ACIP) providing additional detail on the …read more
Source:: Yahoo Finance
